i greatly respect your superior knowledge of the pharmaceutical business which far exceeds mine. But I think if we've got a blockbuster, world leading drug in 2591 for multiple neurological development disorders, and potentially for neuro-degenerative conditions as well, and the European and Asian markets are at least as big as North America, why wouldn't a major European pharmaceutical company be interested in rights to get our product licenced and marketed in the rest of the world, while Acadia develops the North American market. I don't think it's wise for us to put all our eggs in one basket so to speak by dealing exclusively with Acadia for everything we have to offer. Acadia has yet to demonstrate any runs on the board in progress for licencing Daybue in Europe or the UK as yet. I think we've got a lot to gain in terms of promoting our own organic growth and developing our own inhouse resources by extending our partnerships to at least one more major pharma.
NEU Price at posting:
$24.98 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)